Rainbow Children's Medicare
- Market cap
- ₹ 11,870 Cr.
- P/E
- 42.7x
- P/B
- 7.39x
- 52-week range
- 1,084 – 1,610
- ROE
- 16%
- ROCE
- 17%
- Dividend yield
- 0.3%
- Debt / equity
- 0.54
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Rainbow Children's Medicare Limited is an India-based company, which is engaged in the business of rendering medical and healthcare services. The Company is a multi-specialty pediatric and obstetrics and gynecology hospital operating across approximately 20 hospitals and five outpatient clinics, spread across seven Indian cities, with a capacity of 2,035 beds. It offers pediatric services under Rainbow Children’s Hospital, which include newborn and pediatric intensive care, pediatric multi-specialty services and pediatric quaternary care (including multi-organ transplants). Its women care services under Birthright by Rainbow that offers perinatal care services, which include normal and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility care, along with gynecology services. It also operates pediatric Diplomate of National Board (DNB) training programs in private healthcare, offering post-graduate residential DNB and fellowship programs.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Rainbow Children's Medicare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)42.7 against a typical 48.9: cheaper than most peers (1st = cheapest).17th of 40
- Sales growth+33.1% against a typical +21.1% from a year earlier.10th of 34
- Profit growth+16.7% against a typical +13% from a year earlier.15th of 31
- Share price, 3 months−18.8% against a typical −10.9%.24th of 34
- Size₹ 11,870.3 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).10th of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA | Stable | 29 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 29 Sep 2026 | Reaffirmed | [ICRA]AA | — | ICRA | — | |
| 14 Aug 2025 | Reaffirmed | [ICRA]AA | — | ICRA | — |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 31 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve Unaudited (Standalone & Consolidated) Financial Results for the quarter ended September 30, 2026 and other business matters. |
| 30 Jul 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 23 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 28 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 26 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 24 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 333 | 336 | 341 | 330 | 417 | 398 | 370 | 353 | 445 | 445 | 460 | 470 |
| Expenses | 215 | 218 | 236 | 236 | 270 | 264 | 255 | 249 | 296 | 298 | 315 | 335 |
| Operating Profit | 118 | 118 | 106 | 94 | 147 | 134 | 115 | 104 | 149 | 147 | 145 | 135 |
| OPM % | 35% | 35% | 31% | 28% | 35% | 34% | 31% | 29% | 33% | 33% | 31% | 29% |
| Other Income | 8 | 9 | 13 | 12 | 11 | 13 | 15 | 20 | 8 | 11 | 4 | 13 |
| Interest | 13 | 14 | 17 | 18 | 18 | 18 | 18 | 18 | 19 | 20 | 20 | 21 |
| Depreciation | 27 | 28 | 32 | 34 | 35 | 35 | 34 | 34 | 36 | 40 | 41 | 42 |
| Profit before tax | 85 | 85 | 69 | 53 | 105 | 94 | 77 | 71 | 102 | 98 | 87 | 84 |
| Tax % | 26% | 26% | 26% | 26% | 25% | 27% | 27% | 25% | 26% | 24% | 10% | 26% |
| Net Profit | 63 | 63 | 51 | 40 | 79 | 69 | 57 | 54 | 76 | 74 | 78 | 63 |
| EPS in Rs | 6.2 | 6.12 | 5.02 | 3.89 | 7.77 | 6.76 | 5.55 | 5.27 | 7.41 | 7.14 | 7.59 | 5.96 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 22%
- 5 Years
- 21%
- 3 Years
- 13%
- TTM
- 18%
- 10 Years
- 31%
- 5 Years
- 44%
- 3 Years
- 6%
- TTM
- 11%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 7%
- TTM
- —
- 10 Years
- 17%
- 5 Years
- 19%
- 3 Years
- 17%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Rainbow Children's Medicare | ₹ 1,214.70 | ₹ 11,870 Cr. | 42.7x | 7.4x | 16% | — |
| Apollo Hospitals Enterprise | ₹ 7,730.00 | ₹ 1,09,249 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 815.00 | ₹ 79,325 Cr. | 71.3x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 712.90 | ₹ 53,821 Cr. | 67.2x | 7.2x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 644.75 | ₹ 56,272 Cr. | 101.6x | 9.2x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,646.90 | ₹ 33,586 Cr. | 47.5x | 9x | 19.9% | 10.3% |
Management
- Ramesh Kancharla
- Chairman of the Board, Managing Director
- Abrarali Dalal
- Chief Executive Officer
- Vikas Maheshwari
- Chief Financial Officer
- Shreya Mitra
- Compliance Officer, Company Secretary
- Dinesh Kumar Chirla
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.